Search Results

21 - 30 of 282 items :

  • pharmacokinetics x
  • Clinical Medicine x
Clear All
The Use of Methotrexate in Dermatology / Upotreba metotreksata u dermatologiji

with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85. 18. Chladek J, Simkova M, Vaneckova J, Hroch M, ChladkovaJ, Martinkova J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008;64(4):347-55. 19. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of

Open access
Steroid pharmacokinetics: An “overlooked” issue of steroid metabolism in acute and chronic disease

References 1. Sefar S, Degoricija V. About drug dialyzability. Acta Clin Croat 2003;42:257-26. 2. Al-Habet SM, Rogers HJ. Methylprednisolone pharmacokinetics after intravenous and oral administration. Br J Clin Pharmacol 1989;27:285-90. 3. Venkatesh B, Myburgh J, Finfer S, Webb SA, Cohen J, Bellomo R, et al. The ADRENAL study protocol: Adjunctive corticosteroid treatment in critically ill patients with septic shock. Crit Care Resusc 2013;15:83-8. 4. Frey BM, Frey FJ. Clinical pharmacokinetics of

Open access
Analytical Methodologies for the Stereoselective Determination of Sibutramine: An Overview

)-sibutramine: comparison with (RS)-sibutramine and (S)-sibutramine. Indian J Physiol Pharmacol. 2007;51(2):175-178. 5. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. - A review of the metabolic effects of sibutramine. Curr Med Res Opin. 2005;21(3):457-468. 6. Glick SD, Haskew RE, Maisonneuve IM, et al. - Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol. 2000;397:93-102. 7. Noh K, Bae K, Min B, et al. - Enantioselective pharmacokinetics of sibutramine in rat. Arch Pharm Res. 2010

Open access
In Vitro Interactions of Diclofenac with Several Types of Food

;37:937-945. 5. Gan TJ. - Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010;26:1715-1731. 6. Davies NM, Anderson KE. - Clinical Pharmacokinetics of Diclofenac. Clin Pharmacokinet. 1997;33:1-20. 7. Hinz B, Chevts J, Renner B, et al. - Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol. 2005;59:80-84. 8. Walter K, von Nieciecki A. - Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation with enteric-coated pellets. Arzneimittel-Forschung-Drug Res

Open access
CYP3A5 Polymorphism In Serbian Paediatric Epileptic Patients On Carbamazepine Treatment

, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav 2014; 37C:59-70. 6. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50(1):1-23. 7. Thorn CF, Leckband SG, Kelsoe J, et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics 2011; 21(12):906-10. 8. Jankovic SM, Jovanovic D, Milovanovic JR. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. Methods Find Exp Clin Pharmacol

Open access
Formulation Studies of Solid Self-Emulsifying Drug Delivery System of Ivermectin

improved dosing schedule for ivermectin as a microfilaricidal agent against onchocerciasis. Acta Trop 1997;68(3):269-75. 5. Camargo JA, Sapin A, Nouvel C, et al. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physicochemical characterization. Drug Dev Ind Pharm 2013;39(1):146-55. 6. Canga AG, Sahagun Prieto AM, Diez Liebana MJ, et al. The pharmacokinetics and interactions of ivermectin in humans-a mini-review. AAPS J 2008;10(1):42-6. 7. Chaudhari PD, Motewar PP, Sherekar

Open access
The Effects of Cisplatin and Its PT(II) Analogue on Oxidative Stress of Isolated Rat Heart/ Efekti Cisplatine I PT(II) Analoga Cisplatine Na Oksidacioni Stres Izolovanog Srca Pacova

Abstract

To date, numerous platinum (II) complexes have been successfully used in the treatment of different types of cancer. Therapeutic platinum complexes are different in terms of their structure, chemical reactivity, solubility, pharmacokinetics and toxicity. The aim of our research was the evaluation of cardiotoxicity of dichloro-(ethylendiamine) platinum (II) in a model of isolated rat heart using the Langedorff technique. Oxidative stress was assessed by determination of superoxide anion radical, hydrogen peroxide, Thiobarbituric Acid Reactive Substances and nitric oxide levels from coronary venous effluent. All reagents were perfused at increasing concentrations from 10-8 to 10-4 M for 30 minutes. In this paper, we report that substances administered at higher doses did not induce dose-dependent effects on oxidative stress markers. The results of this research may be of great interest for future studies in this area. There are many novel platinum compounds that had previously demonstrated antitumour activity, and these types of experiments in our study can assist in the examination of their cardiotoxicity. These results could be helpful for understanding dose-dependent side effects of existing and novel platinum compounds

Open access
Combination of Ropivacaine and Lidocaine for Long Lasting Locoregional Anesthesia

References 1. Cuvillon P, Nouvellon E, Ripart J, Boyer JC, Dehour L, Mahamat A, et al. A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. Anesth Analg. 2009;108:641-649. 2. Ye F, Feng YX, Lin JJ. A ropivacaine-lidocaine combination for caudal blockade in haemorrhoidectomy. J Int Med Res 2007;35:307-313. 3. Hansen TG. Ropivacaine: A

Open access
SURVIVE: let the dead help the living—an autopsy-based cohort study for mapping risk markers of death among those with severe mental illnesses

Abstract

Background: Forensic autopsy strategies may improve differential diagnostics both post-mortem and ante-mortem and aid in clinical settings concerning preventive efforts for premature mortality. Excess mortality and reduced life expectancy affect persons with severe mental illnesses (SMI) for multi-faceted reasons that remain controversial. Somatic conditions, medical treatment and lifestyle diseases, which are primarily examined in the living, contribute to premature deaths. The underlying pathophysiological mechanisms are unclear, though, and the benefits of a focused, standardised autopsy remain unproven. We have developed and implemented an optimised molecular–biological autopsy for deceased persons with SMI. Our aim is to map the occurrence of 1) somatic diseases and organ changes; 2) metabolic syndrome; 3) use and abuse of alcohol, pharmaceuticals and psychoactive substances; 4) pharmacokinetic and pharmacodynamic factors in the metabolism of pharmaceuticals; and 5) genetic variations (acquired and/or congenital) in sudden cardiac death. Additionally, we hope to contribute to diagnostic treatments and preventive measures to benefit those living with SMI. Methods: SURVIVE: let the dead help the living is a prospective, autopsy-based study on 500 deceased persons with SMI subjected to forensic autopsies under the Danish Act on Forensic Inquests and Autopsy. The autopsies followed an extended, standardised autopsy protocol comprised of whole-body computed tomography scanning, magnetic resonance imaging of the heart and brain and an extended forensic autopsy, including a wide panel of analyses (toxicology, microbiology, genetics, histology and biochemical analysis). Additionally, post-mortem data were linked to ante-mortem health data extracted from Danish national health registers.

Discussion: The SURVIVE autopsy procedure, including tissue sampling and bio banking, has been shown to be effective. We expect that the SURVIVE study will provide unique opportunities to unravel the mechanisms and causes of premature death in persons with SMI. We also expect that identifying prognostic biomarkers for comorbidities will contribute to prevention of premature deaths and comorbidities in persons with SMI.

Open access
Development of a Capillary Electrophoresis Method for the Separation of Fluoroquinolone Derivatives in Acidic Background Electrolyte

Abstract

Introduction: Antibacterial quinolones class comprises a series of synthetic antibacterial agents, following the model of nalidixic acid. Because of their common 6-fl uorosubtituent on the quinolone ring, fluroquinolones are the most potent analogues with extended spectrum of activity and great pharmacokinetic properties. The applicability of capillary zone electrophoresis for the separation of fl uoroquinolones in acidic background electrolyte has been studied, our aim being the development of a capillary zone electrophoresis method for the simultaneous separation of six fl uoroquinolones and also to optimize the analytical conditions. The six studied fl uoroquinolones were ciprofloxacin, enoxacin, enrofloxacin, moxifloxacin, ofloxacin and sarafloxacin.

Material and methods: Preliminary, we studied the electrophoretic behavior of six fluoroquinolones in an acidic pH, which highlighted the possibility of developing a separation method in this area of pH. Electrophoretic parameters infl uencing separation performance were studied and optimized.

Results: A fast and reliable method has been developed, using a background electrolyte containing 100 mM phosphoric acid and the following conditions: applied voltage: + 25 kV, temperature: 20°C, injection pressure 30 mbar - 5 sec, UV detection at 280 nm, capillary: 60 cm (52 cm effective length) x 50 μm, analyte concentration: 167 μg/ml. The separation of the studied fl uoroquinolones was achieved in less than 8 minutes.

Conclusions: Capillary zone electrophoresis using an acidic background electrolyte proved to be an efficient tool in the separation of fluoroquinolones from different generations. Also the proposed methods are particular environment-friendly replacement and improvement of a common high performance liquid chromatography determination with rapid analysis time without using any organic solvents.

Open access